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Previewsintracellular calcium levels in cells from
a patient with IPAH obtained at the time of
lung transplantation. Taken together, these
findings provide a link between an intrinsic
metabolic abnormality of pulmonary
vascular cellular mitochondria, affecting
acute vasoconstriction and resistance to
apoptosis, and vascular remodeling.
While the studies by Sutendra et al.
provide important connections between
a variety of independent observations
and lead to a plausible mechanism of
upstream pathogenesis of PAH, there
are a number of unanswered questions:
1. The degree of vasculopathy seen in
chronic hypoxia is quite modest
compared to that observed in PAH,
and the former is generally reversible
upon restoration of normoxic condi-
tions, while the latter is, at least for
now, irreversible. Accordingly, the
extrapolation from hypoxic pulmo-
naryhypertension toPAH is tenuous.
2. The translation of findings in animal
models of PAH, particularly mono-
crotaline-induced PAH, to the clin-
ical arena has been disappointing,
with a number of drugs or other
interventions demonstrating dra-
matic results in animals and either
no effect or, at best, a modest
effect in patients.
3. The role of the endothelial cell in the
pathogenesis of PAH remains314 Cell Metabolism 12, October 6, 2010 ª20unclear, and these experiments
did not include studies of these
cells. Thus, it remains unclear
whether endothelial dysfunction is
an early or late event in the patho-
genesis of PAH or whether an
endothelial-smooth muscle inter-
action early in the disease process
is important.
4. The impact on proliferation of
human cells exposed to the meta-
bolic inhibitors was not investi-
gated, an observation that would
have provided a much stronger
link between altering intracellular
calcium and remodeling.
5. The authors examined cells from a
single patient with ‘‘IPAH.’’ Whether
their observations will be reinforced
with experiments from cells ob-
tained from other patients with this
or other forms of PAH is unclear.
Despite these limitations, Sutendra
et al. have advanced our understanding
of the pathogenesis of pulmonary vas-
cular disease and have pointed us in the
direction of a new and selective target
for therapy. While more work needs to
be done before a formal clinical trial
of metabolic inhibitors should be enter-
tained, the prospect of reversing the
vasculopathy of PAH is exciting and
brings a new set of colleagues—experts
in metabolism—into the battle.10 Elsevier Inc.REFERENCES
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Replacement of nonvascular cartilage by bone and bone marrow is a critical step in bone development. In
a recent issue of Developmental Cell, Maes et al. (2010) report that a distinct population of immature precur-
sors of bone-forming cells migrate into the cartilage in intimate association with invading blood vessels.The development of most bones, such as
bones in the limbs and spine, proceeds
via a two-stage process known as endo-
chondral ossification. The architecturalmodeling of a bone takes place in the
location of the future bone via assembly
of a template. The template consists of
hyaline cartilage, a nonvascular tissuecomposed of chondrocytes dispersed
within a complex extracellular matrix. As
the template grows and takes on the
shape of the future bone, chondrocytes
Figure 1. Schematic Drawing of the Middle Portion of a Developing
Endochondral Bone
Asdescribed in the text,matureosteoblasts (Col1/lacZ+cells) formcortical bone
on the outside, while immature precursors (Osx/lacZ+ cells) invade the cartilage
and reach the primary ossification center in association with blood vessels.
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template stop proliferating;
express a characteristic set of
transcription factors, cyto-
kines, and matrix molecules;
increase in size (become
hypertrophic); and activate
apoptotic cell-death mecha-
nisms. These changes set in
motion a process that results
in the conversion of the
nonvascular cartilage template
to an organ with compact
bone tissue on the surface
(cortical bone) and spongy
(trabecular) bone tissue and
highly vascularized bone
marrow inside. During the past
25 years, a number of signifi-
cant studies have provided
insights into the molecular
mechanisms regulating differ-
entiation of chondrocytes andosteoblasts frommesenchymal precursor
cells and signals that control penetration
of blood vessels into hypertrophic carti-
lage during endochondral ossification.
However, the origin of the osteoblastic
cells that produce the spongy/trabecular
bone (also referred to as the primary
spongiosa) in which hematopoietic bone
marrow niches are established has re-
mained uncertain. Many cellular sources
have been considered, including peri-
chondrial cells on the cartilage surface,
hypertrophic chondrocytes, pericytes
associated with blood vessels pene-
trating into the cartilage, and progenitor
cells circulating in the blood. Experi-
mental support for the notion that osteo-
blasts may be generated from all these
sources under various conditions exists,
but no study providing definitive identifi-
cation of the major origin of the cells that
form the primary spongiosa during bone
formation has been published, until now.
In a recent study, Maes et al. (2010)
advance the field by presenting compel-
ling data in support of the conclusion
that osteoblasts in the primary spongiosa
are derived from immature precursors
that invade into the cartilage in intimate
association with blood vessels (Figure 1).
Differentiation of osteoblasts from
mesenchymal cells requires the transcrip-
tion factor Osterix (Osx) (Nakashima et al.
2002). Osterix is expressed at an early
stage in the osteoblastic lineage, before
cells reach the fully differentiated stageand start synthesizing extracellular com-
ponents such as collagen type I. Taking
advantage of the difference in timing of
Osterix and collagen I expression, Maes
et al. (2010) generated two transgenic
mouse lines in which Cre recombinase
(controlled either by the Osterix or
a collagen I promoter) could be activated
in a tamoxifen-dependent manner to
induce expression of b-galactosidase/
lacZ in osteoblastic lineage cells. By
controlling the timing of exposure of
developing transgenic embryos in the
two lines to a pulse of tamoxifen relative
to the timing of endochondral ossification
in the limbs, the investigators labeled
early- (Osx/lacZ+) and late-stage (Col1/
lacZ+) osteoblastic lineage cells as they
differentiated in the perichondrial regions
of developing bones. Electron micros-
copy suggested that about 60% of the
Osx/lacZ+ cells were immature cells
(large nuclei and sparse endoplasmic
reticulum), and about a third of these cells
were found in pericyte-like fashion along
endothelial cells in blood vessels. The
remaining Osx/lacZ+ cells were classified
as early osteoblasts. In contrast, Col1/
lacZ+ cells appeared to be fully differenti-
ated osteoblasts, engaged in the process
of forming cortical bone. Not surprisingly,
further analyses indicated that some of
the immature Osx/lacZ+ cells serve as
precursors of the mature osteoblasts.
However, the intimate association with
blood vessels raised the possibility thatCell Metabolism 12, October 6, 2they could have additional
fates and functions.
Remarkably, as the two
cell populations were fol-
lowed during endochondral
ossification, 70% of Osx/
lacZ+ cells were found
in the spongy/trabecular
bone region inside the
developing bone, whereas
Col1/lacZ+ cells remained
predominantly on the
outside, in the cortical re-
gion. Thus, a major subset
of Osx/lacZ+ cells serve
as precursors of the osteo-
blasts that form the primary
spongiosa. Maes et al.
(2010) also examined
whether hypertrophic chon-
drocytes make a contribu-
tion to trabecular bone
formation during endo-chondral ossification, a possibility that
has long been considered, by following
the fate of hypertrophic chondrocytes.
They found that although some of the
chondrocyte-like cells at the cartilage/
perichondrial junction may contribute to
bone formation, the majority of the hyper-
trophic chondrocytes do not become
osteoblasts in the central region of the
primary spongiosa, at least in mice (and,
as pointed out by Maes et al., in the
‘‘time span of our studies’’).
An important question raised by these
data is the mechanism by which only
immature osteoblastic cells are recruited
from the perichondrium into the primary
ossification center together with vascular
endothelial cells and osteoclasts. Based
on previous studies (Zelzer et al., 2001,
2004) demonstrating that hypertrophic
chondrocytes express high levels of
VEGFA, a potent stimulator of both endo-
thelial and osteoclastic migration, it
seems likely that the mechanism includes
VEGF-associated activities. One possi-
bility suggested by the present study is
piggybacking of immature osteoblast
precursors on vascular endothelial cells
as the vessels sprout and extend from
the perichondrial region toward the hyper-
trophic cartilage inside the forming bone.
Interestingly, Maes et al. (2010) provide
preliminary data suggesting that Osx-
positive cells express high levels of
VEGF and of Angiopoietin-1 and PDGRb,
molecules that play a role in interactions010 ª2010 Elsevier Inc. 315
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Finally, it is possible that immature osteo-
blastic progenitors differ from mature
osteoblasts in that they, like vascular
endothelial cells and osteoclasts, are
able to respond to migratory signals,
such as VEGF.
This study also provides a basis for ad-
dressing problems that go beyond the
realm of bone formation. For example,
with the osteoprogenitor population
responsible for the formation of the
trabecular bone inside endochondral
bones defined and sorting techniques for
the isolationof thesecells frommixedpop-
ulations available, the question of whether
or how these cells and their extracellular
matrix products contribute to the forma-
tion of hematopoietic stem cell niches
may now be addressed using the subcap-316 Cell Metabolism 12, October 6, 2010 ª20sular kidney assay that Chan et al. (2009)
recently used to demonstrate that endo-
chondral ossification is required for hema-
topoietic stem cell niche formation. Given
that Nestin-positive mesenchymal stem
cells in bone marrow were recently re-
ported to constitute an essential compo-
nent in the hematopoietic stem cell niche
(Mendez-Ferrer et al., 2010), it will be im-
portant to examine whether they interact
with or are related to these Osterix-
expressing immature cells that give rise
to the osteoblastic cells forming the
primary spongiosa in endochondral bone.REFERENCES
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